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Abstract  
The large costs associated with modern drug discovery mean that governments and regulatory bodies 
need to provide economic incentives to promote the development of orphan drugs, i.e., of medicinal 
products that are designed to treat rare disease that affect only small numbers of patients. Under EU 
legislation a medicine can only be authorised for treating a specific rare disease if it is not similar to 
other orphan drugs already authorised for that particular disease.  This paper discusses the use of 2D 
fingerprints to calculate the Tanimoto similarity between potential and existing orphan drugs for the 
same disease, and presents logistic regression models correlating these computed similarities with the 
judgements of human experts.   
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Teaser: Similarity of medicines in the context of the orphan drug legislation. 
Highlights:  
x Authorisation and evaluation of orphan drugs. 
x Similarity in the in the context of the orphan drug legislation. 
x 2D fingerprints used to evaluate similarity of orphan medicines. 
x Human assessment versus computer assessment. 
 
Introduction 
An orphan drug is a medicinal product intended for the treatment of a rare disease that affects only a 
small number of patients (less than 200,000 individuals in the USA [Orphan drug Act, Public Law 97-
414, 4 January 1983 (US)] or less than five in 10,000 individuals in the EU [Regulation (EC) No. 
141/2000 of the European Parliament and Council of 16 December 1999]) [1][Heemstra, H.E., PhD 
thesis, University of Utrecht, 2009 at http://dspace.library.uu.nl/handle/1874/37546].  This means that 
orphan drugs are not an immediately attractive market for the pharmaceutical industry since the 
limited numbers of potential patients are unlikely to yield revenues sufficient to cover the huge costs 
of modern-day drug discovery programmes [2, 3].  For this reason, regulatory authorities have 
brought forward legislation to encourage pharmaceutical companies and research groups to develop 
orphan drugs by providing a range of incentives: the 86$¶VOrphan Drug Act was introduced in 1983 
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and WKH(8¶VRegulation (EC) No 141/2000 in 2000.  These offer a similar range of incentives, with 
those in the EU including grants, market exclusivity, the possibility of an accelerated review, financial 
incentives provided by some member states and European programmes, fee reductions, free protocol 
scientific advice, and regulatory support [1, 4].    These measures have been highly successful, to the 
point that orphan drugs comprised over half of the new molecular entities approved by the US Food 
and Drug Administration in 2015 [5].  
Market exclusivity is arguably the most important of these incentives: under the EU 
legislation, a pharmaceutical company that develops an orphan drug for a specific, rare therapeutic 
indication is given a ten-year period of market exclusivity, during which no products that are 
considered to be similar to that orphan drug cannot be accepted or authorised by any European 
regulatory competent authority.  The first orphan drug approved for a certain rare disease hence has 
less competition than does a conventional medicinal product, which should encourage pharmaceutical 
companies to invest in research aimed at identifying novel medicines for such diseases.   
 How then should the similarity, or non-similarity, of two molecules be judged?  According to 
article 3 (3) of the Commission Regulation (EC) No 847/2000, a similar medicinal product is defined 
as a medicinal product containing a similar active substance to that included in an orphan drug already 
authorised in the EU for the same therapeutic indication [6].    The assessment of similarity between 
two medicinal products (article 8 of Regulation (EC) No 141/2000) takes three criteria into account: 
the molecular structure; the mechanism of action; and the therapeutic indication.  Two medicinal 
products will be considered not similar if there are significant differences under one or more of these 
three criteria [7].  Thus far, the European Medicines Agency (EMA), the regulatory authority that is 
responsible for evaluation of medicines throughout the EU, has used human judgments of similarity 
when assessing new medicines for rare diseases.  In a previous paper, we described the first stage of a 
research project to provide computational support for these judgements [9]; here, we extend this work 
by testing further types of 2D fingerprint and describe a web application for this purpose that is based 
on open-source chemoinformatics software.   
It should be noted that the European Commission has recently undertaken a public 
FRQVXOWDWLRQRQWKHFRQFHSWRIµVLPLODUPHGLFLQDOSURGXFW¶LQWKHFRQWH[WRIRUSKDQGUXJOHJLVODWLRQ
since it is now over 15 years since the implementation of Commission Regulation (EC) No 847/2000 
and the Commission aims to collect views, relevant evidence and information from stakeholders to 
help it develop its thinking in this area [8].  The definition of similarity in the consultation document 
is still quite vague and leaves considerable room for subjective interpretation, and we hence believe 
that the quantitative methodology described in this article provides an important contribution to the 
ongoing debate.   
The next section describes the methods that were used by Franco et al. [9] and that form the 
basis for the experiments reported here.  The paper continues with the results that were obtained when 
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these methods were used with open-source fingerprint software, and this is followed by a description 
of a software application that we have developed using these results.  Further details of this work are 
reported by Franco [Franco. P., thesis, University of Sheffield, 2015 at 
http://etheses.whiterose.ac.uk/10148/] 
 
Methods  
The judgement as to whether a new medicine should be authorised as an orphan drug status in the EU 
is taken by a panel of human experts, the EMA¶V Committee for Medicinal Products for Human 
Use(CHMP).  To mimic this process, Franco et al. [9] selected a set of 100 pairs of bioactive 
substances from the Drug Bank 3.0 database [10], and each of 143 quality experts from the EU, Japan 
and the USA was asked to consider each such pair and to decide whether they were, or were not, 
similar to each other.  These binary assessments LH³VLPLODU´RU³QRWVLPLODU´were then compared 
with similarity values obtained by calculating the similarity between the 2D fingerprints describing 
the two molecules using the Tanimoto similarity coefficient [11].  The proportion of the expert 
assessors deciding that each pair was similar was then correlated with the computed similarity values 
using logistic regression.  Specifically, regression models were developed to predict the probability 
(p) that the human assessors would decide that a pair of molecules were indeed similar given the value 
(x) of the Tanimoto similarity coefficient for that pair.  The models are thus of the form  ሺ݌ሻ ൌ  ൬ ݌ͳ െ ݌൰ ൌ ܽ ൅ ܾݔ 
where a and b are the regression coefficients.  The models, which had been trained using the 
DrugBank data, were then shown to possess considerable predictive power when they were applied to 
real data that had been previously evaluated by the CHMP.  Specifically, the test-set contained 100 
molecule-pairs in which one molecule was an existing orphan drug for some specific rare disease and 
the other was a molecule that had been submitted to the CHMP for consideration for orphan drug 
status for that disease1.  Given the success of this study, it was concluded that measures of similarity 
based on 2D fingerprints might provide a useful source of information to the CHMP during the 
evaluation of a new application for orphan-drug status.   
 The study evaluated six different types of 2D fingerprint (specifically BCI, Daylight, ECFC4, 
ECFP4, MDL and Unity), but all of them were proprietary in nature and thus not necessarily available 
to any organisation or individual wishing to use our methods.  The work described here was 
undertaken to overcome this limitation of our previous study, and involved using fingerprints 
available in the open-source CDK and RDKIT systems (at https://sourceforge.net/projects/cdk/ and 
http://www.rdkit.org/RDKit_Docs.current.pdf, respectively).  Specifically, the following twelve types 
                                                          
1
 It is not possible to include the CHMP molecules on grounds of commercial confidentiality, but the DrugBank 
dataset is available as supplementary information for the paper by Franco et al. at 
https://jcheminf.springeropen.com/articles/10.1186/1758-2946-6-5 
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of fingerprint were generated, as implemented in the KNIME pipelined data analysis system (at 
http://www.knime.org): CDK Extended, CDK Standard, Estate, PubChem, MACCS, Morgan, Feat 
Morgan, Atom Pair, Torsion, RDKit, Avalon, and Layers.  These fingerprints cover all of the many 
types used in current chemoinformatics systems (circular, hashed, fragment dictionary, and 
topological patterns) [12].  Logistic regression models were developed for each type of fingerprint, 
correlating the Tanimoto similarity for a pair of molecules with the probability of the human experts 
deciding that that pair was similar; the training dataset was the 100 pairs of molecules in the 
DrugBank dataset; and the resulting models were then validated using the 100 pairs of molecules in 
the CHMP test dataset.  
 
Results and discussion 
The results obtained with the DrugBank training set will be illustrated using the CDK Extended 
fingerprint, a hashed fingerprint that is similar in concept to Daylight fingerprints and that encodes all 
linear paths up to eight atoms in length; in addition, the fingerprint contains bits detailing the numbers 
of fused and unfused rings.  
Figure 1 plots the proportion of the expert assessors who judged a molecule-pair as being 
similar (Y-axis) against the computed fingerprint similarity score for that molecule-pair (X-axis).  
There is a well-marked separation of the similar pairs (marked in green) and the non-similar pairs 
(marked in blue), with the smaller Tanimoto values dominating the lower left portion of the curve 
(i.e., only a small proportion of the experts judged that a pair should be considered similar) and the 
larger Tanimoto values the upper right portion (i.e., most of the experts judged that a pair should be 
considered similar).  The solid line in this figure represents the estimated probability of being similar 
as predicted by the logistic regression model, together with the 95% confidence limits for this 
prediction (the dotted lines).  The values of a and b in the regression model for this fingerprint were -
16.761 and 2.881 respectively, with these values being statistically significant (p = 0.0012) and with 
the Nagelkerke R2 value of 0.917 indicating a good fit of the model to the data.  The CDK Extended 
fingerprint gave the highest Nagelkerke value for all of the twelve fingerprints tested here; the lowest 
value of 0.690 was obtained with the EState fingerprint (which encodes structural keys but is, at 79 
bits, by far the shortest of all the fingerprints). 
If a logistic regression model is to be used predictively then one must be able to identify an 
appropriate threshold similarity for deciding that two molecules should indeed be considered as 
similar.  Let t denote the threshold similarity such that a pair of molecules are predicted to be similar 
LIWKHLUFRPSXWHGVLPLODULW\LV(?(?t DQGSUHGLFWHGQRWWREHVLPLODULI(?(?t.  The predictions resulting from 
use of a particular value for t can then be compared with the judgements of the 143 experts, thus 
allowing the calculation of the numbers of true positives (TP), true negatives (TN), false positives 
(FP) and false negatives (FN) where, e.g., TP is the number of cases where the majority of the experts 
judged two molecules to form a similar molecule-pair and where those two molecules had a computed 
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VLPLODULW\(?(?t.  Knowledge of these four values then allows the plotting of a receiver operating 
characteristic (ROC) curve, which demonstrates the relationship between the specificity 
(TN/(TN+FP)) and the sensitivity (TP/(TP+FN)) as the threshold, t, is systematically varied.  The 
resulting area under the ROC curve, or AUC, was 0.992, this very high value indicating the ability of 
the CDK Extended fingerprint to discriminate between similar and non-similar pairs of molecules.  
This was the largest AUC value obtained across the twelve fingerprints, with the EState fingerprint, as 
with the Nagelkerke statistic, giving the lowest value (of 0.929). 
 Several other measures based on these four variables (i.e., TP, TN, FP and FN) are available 
in the literature to measure the effectiveness of a predictive system.  Those computed here were the 
precision, the accuracy, the F index, the Youden index, and 0DWWKHZ¶V FRUUHODWLRQ FRHIILFLHQW, as 
described by Franco et al. [9].  These five statistics were computed as t was varied, thus enabling us to 
identify that threshold similarity value that gave the best predictions, where this optimal value was 
taken to be that which gave the largest values for the precision, the accuracy, the F index, the Youden 
index and the Matthews coefficient whilst at the same time providing acceptable values for the 
sensitivity and the specificity.  For the CDK Extended fingerprint, a value of 0.610 for t was found to 
be the best, and this was then used for the analysis of the CHMP test dataset.  An entirely comparable 
process was used to determine the optimal similarity threshold for each of the other eleven types of 
fingerprint.  In five cases (MACCS, Morgan, Feat Morgan, Torsion and Layers), two different values 
of t were found to yield comparable results on the training dataset so just a single value (specifically, 
those obtained with the larger of the two t values) is quoted in the results in Table 1 that are discussed 
below. 
The regression models developed on the DrugBank training dataset were then applied to the 
CHMP test dataset, as detailed in Table 1.  Each row of the table is associated with one type of 
fingerprint and lists the a and b coefficients from the regression model, the Nagelkerke R2  and AUC 
values for that model, the threshold similarity t as derived above, and finally the number of test cases 
that were predicted correctly, where a correct prediction is a pair of molecules for which the 
prediction from the model, (i.e., similar or not similar) mirrors that arrived at by experts comprising 
the CHMP panel.  For comparison, the bottom row of the table contains the corresponding data for the 
BCI (Barnard Chemical Information) fingerprint that was found to give the best overall level of 
performance in our previous comparison of six different types of proprietary fingerprint.  Inspection 
of Table 1 shows that all but three of the fingerprints (Estate, Atom Pair and RDDKit) were able to 
predict successfully the similarity or non-similarity of 95 or more of the pairs of molecules in the test 
dataset, with the Morgan fingerprint resulting in only a single incorrect prediction (despite it 
achieving only moderate R2 and AUC values in the training stage).  The incorrect prediction was for a 
pair of active substances in which both had complex structures and molecular weights in excess of 
500.  It was not just the Morgan fingerprint that failed here, since all of the models that were 
developed failed to make a correct prediction for this particular case.  
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Data fusion, or consensus scoring, has been found to be of considerable value for similarity-
based virtual screening [13] and we have adopted this approach to the present context.  Specifically, 
assume that each of several different fingerprints is used to make a prediction for a pair of molecules: 
then the final prediction is that given by the majority of the fingerprints.  It was found that 99 correct 
predictions were obtained using both all of the CDK fingerprints (i.e., four or more of them giving the 
same prediction) or all twelve fingerprints (i.e., seven or more of them giving the same prediction).  
The incorrect predictions were again for the pair of molecules discussed in the previous paragraph.   
Since different fingerprints capture different characteristics of molecular structure and since the open-
source nature of CDK and RDKit provides a range of such fingerprints, a consensus approach such as 
this would seem to be appropriate for future applications of our approach.    
 One such application that has been developed is a KNIME-based system that is now being used 
to support assessors throughout the EU who assist CHMP in coming to a decision as to whether a 
medicine for a rare disease should be approved..  The assessors do this by producing an evaluation 
report on similarity in which they comment on the extent to which the new active substance is indeed 
sufficiently distinct from existing orphan drugs for that indication.    The application takes as input the 
SMILES linear notations of the two (or more) molecules that are to be compared; generates the required 
fingerprints (initially CDK Extended, CDK Standard, Avalon and Layers as these were the ones where 
the computed similarity values correlated most strongly with the BCI fingerprint that performed best in 
our previous study); computes the Tanimoto similarity coefficient using each of these fingerprints; and 
outputs an Excel spreadsheet containing the coefficient values and the corresponding probabilities of 
being judged similar as calculated using the appropriate regression models from Table 1.  The assessor 
can then use this spreadsheet when coming to a conclusion as to the novelty or otherwise of the 
submitted molecule, the report that is submitted to the EMA being based not just on the fingerprint-
based structural similarity but also on the reported therapeutic indication and mode of action.  The sets 
RI DVVHVVRU UHSRUWV SURYLGH DQ LPSRUWDQW LQSXW WR WKH &+03¶V ILQDO GHFLVLRQ DV WR ZKHWKHU RU QRW WR
assign orphan drug status to a molecule that has been submitted for consideration.  In addition, of 
course, pharmaceutical companies can use the data in Table 1 to assist them prior to submission of a 
new molecule to the EMA for consideration for marketing authorisation.  
In addition to the 2D fingerprints discussed here, comparable experiments were also 
conducted using two other types of molecular representation [P. Franco, PhD these, University of 
Sheffield, 2015 at http://etheses.whiterose.ac.uk/10148/].  In the first of these, molecules were 
characterised by 23 computed molecular properties (such as molecular weight, logP, molar 
refractivity, numbers of rotatable bonds etc.); and in the second by four further proprietary 
fingerprints produced by the Chemical Computing Group as part of their Molecular Operating 
Environment system (at https://www.chemcomp.com/): two of these ± Typed Graph Distances and 
Typed Graph Triangles ± described the 2D shape of a molecule while the other two ± Typed Atom 
Distances and Typed Atom Triangles ± described the 3D shape of a molecule.  None of these 
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alternative types of molecular representation were found to perform as well as the 2D fingerprints 
used here.  There are, of course, many other ways in which structural similarity can be computed [14, 
15].  A fingerprint is a very simple, LQGHHGFUXGHGHVFULSWLRQRIDPROHFXOH¶V'VWUXFWXUHDQGPRUH
complex similarity measures have hence been described that are based on the maximum common 
subgraph (or MCS), i.e., the largest subgraph common to the graphs describing two 2D molecular 
structures [16, 17].  The MCS provides an intuitive measure of similarity but does have three 
limitations.  First, an MCS can be defined in multiple ways: it may be based upon the numbers of 
matching atoms and/or bonds; and it can be connected, be disconnected, or be disconnected subject to 
the individual components being of at least some threshold size.  Next, a similarity measure can be 
based upon just the MCS (or MCSs if there is more than one) or upon a weighted combination of the 
MCS and of the smaller maximal common subgraphs.  Finally, MCS detection is computationally 
demanding, and many of the MCS algorithms that have been published are non-deterministic or 
approximate in nature.  In view of the very high level of performance achieved in our experiments, we 
believe that 2D fingerprints provide the most appropriate way of investigating the similarity 
relationships pertinent to the registration of orphan drugs.    
 
Conclusions 
Measures of structural similarity based on 2D chemical fingerprints are widely used in medicinal 
chemistry (and in chemoinformatics more generally) for applications such as database clustering, 
diversity analysis and ligand-based virtual screening.  
In our work we have shown how this very common type of structural representation can also be applied 
to the licensing of medicines for rare diseases by regulatory authorities.  Experiments with a range of 
fingerprints that can be generated using widely available, open-source software show that they provide 
measures of Tanimoto-based similarity that correlate well with expert assessments of structural 
similarity; and that logistic regression models based on these similarities and human assessments mirror 
YHU\FORVHO\ WKHILQDOSURQRXQFHPHQWVRI WKH(0$WKH(8¶VUHJXODWRU\DXWKRULty for the licensing of 
orphan drugs.  A software application based on our findings provides a simple tool to support the work 
of EU experts who contribute to the final recommendations made to the EMA by CHMP.    
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Figures and Tables 
 
Figure 1.  Correlation between the probability of a pair of molecules being similar based on human 
judgements and the Tanimoto coefficient using the CDK Extended fingerprint 
 
 
 
Table 1.  Logistic regression models for different 2D fingerprints 
 
Fingerprint a b R2 AUC t Predictions 
CDK Extended  -16.761 2.881 0.917 0.992 0.610 96 
CDK Standard -13.971 2.446 0.905 0.989 0.587 96 
EState -9.642 1.334 0.690 0.929 0.714 91 
PubChem -12.847 1.717 0.772 0.957 0.776 95 
MACCS -9.071 1.398 0.811 0.974 0.750 95 
Morgan -8.204 2.238 0.871 0.982 0.400 99 
Feat Morgan -9.041 1.822 0.876 0.987 0.519 96 
Atom Pair -11.790 2.492 0.879 0.984 0.459 80 
Torsion -6.533 1.877 0.882 0.986 0.370 98 
RDKit -8.249 1.333 0.788 0.964 0.671 73 
Avalon -8.447 1.536 0.881 0.987 0.625 95 
Layers -22.314 3.031 0.877 0.985 0.761 95 
BCI í12.758 2.128 0.906 0.990 0.606 97 
 
